India's pharma sector, which was dependent on China for a long time, is now getting some relief; the reason is the Atmanirbhar Bharat..
Synopsis. Delius Pharma registered a 35 percent rise in sales in FY23 to 24, with plans to set up multiple manufacturing units in India for finished formulation and API production. Delius Pharmaceuticals has said that it has registered a 35 percent increase in sales and turnover in FY 23-24
The drug API Innovation Center has reached a milestone in the development of technology essential to accelerating the U.S. production of lomustine, a critical cancer medication, and will collaborate with St. Louis-based Apertus Pharmaceuticals to expand its manufacturing in Missouri.
Lupin Limited announced that the United States Food and Drug Administration (U.S. FDA) has completed a GMP Inspection of its API manufacturing facility located at Dabhasa, India. The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations.
89bio has struck a deal with China CDMO BiBo Pharma to build a plant which will produce bulk active ingredient for its MASH prospect pegozafermin.
Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to produce lomustine, which is used to treat brain tumors.
Prices of Active Pharmaceutical Ingredients (API), which are used to make formulations, are seeing the biggest-ever drop after Covid-19, bringing relief to the pharma industry that has reported a 50% retreat in API costs.
NORTHUMBERLAND, England and BOSTON, April 3, 2024 /PRNewswire/ -- Prozomix, a UK-based biotech company focused on novel biocatalyst discovery and manufacturing, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Together, Ginkgo and Prozomix aim to build out the production of next generation enzyme plates for active pharmaceutical ingredient (API) manufacturing. This collaboration aims to leverage Ginkgo's Enzyme Services and industry-leading AI/ML models along with Prozomix's existing enzyme libraries and deep experience manufacturing enzyme plates.
Warren Remedies Private Limited, a Wholly Owned Subsidiary of Indoco Remedies Limited has commenced its commercial production on March 24, 2024 from its Greenfield manufacturing facility located at Aurangabad, Maharashtra to manufacture Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs).
This year, Olon's Daptomycin celebrates its 10th anniversary—and the API supplier group has announced the doubling of its production to meet and exceed global demand for the active ingredient.